Moran Artzi1,2, Deborah T. Blumenthal3,4,
Felix Bokstein3,4, Benjamin W. Corn, 4,5, Palmon Mika1,
Orna Aizenstein6, Dafna Ben Bashat1
1The Wohl Institute for Advanced
Imaging, Brain Imaging Center, Tel Aviv Sourasky Medical Center, Tel-Aviv,
Israel; 2Sackler Faculty of Medicine, Tel-Aviv University ,
Tel-Aviv, Israel; 3Neuro-Oncology Service, Oncology Division, Tel
Aviv Sourasky Medical Center, Tel-Aviv, Israel; 4Sackler Faculty
of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 5Radiation
Oncology Unit, Oncology Division, Tel Aviv Sourasky Medical Center, Tel-Aviv,
Israel; 6Department of Radiology, Tel Aviv Sourasky Medical
Center, Tel-Aviv, Israel
Combined
chemo-radiation therapy (RT) is the standard first-line treatment for
glioblastoma (GB). Recently, antiangiogenic-drugs such as bevacizumab have
become routine second-line-therapy for patients with recurrent-GB; however
the effects of this agent on the normal appearing white-matter (NAWM) are yet
unknown. In this work we scanned patients with primary brain tumors before
and after RT and during bevacizumab therapy. DTI was used to evaluate NAWM
changes compared to healthy controls. Changes in diffusivity values were
detected following RT but not during bevacizumab-therapy. Those results
support that post-radiation changes occur, without evidence for additional WM
toxicity from bevacizumab-therapy.
Keywords